<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158858</url>
  </required_header>
  <id_info>
    <org_study_id>0610-02</org_study_id>
    <nct_id>NCT02158858</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis</brief_title>
  <official_title>A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Constellation Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Constellation Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients
      with previously treated Acute Leukemia, Myelodysplastic Syndrome,
      Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis.

      Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with
      Myelofibrosis.

      CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2 Part: Evaluate spleen response</measure>
    <time_frame>By imaging after 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Part: Evaluate the RBC (Red Blood Cell) transfusion independence rate</measure>
    <time_frame>Absence of RBC transfusion and no hemoglobin level below 8 g/dL in the prior 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Part: Evaluate the duration of spleen response by imaging</measure>
    <time_frame>By palpation and imaging after 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Part: Evaluate response category rate</measure>
    <time_frame>Rate of response by IWG-MRT after 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Part: Evaluate the change in patient reported outcomes</measure>
    <time_frame>Changes from baseline in the total symptom score (MFSAF v4.0) and PGIC after 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Part: Evaluate the rate of RBC transfusion and the RBC transfusion dependence rate</measure>
    <time_frame>Average number of RBC units per subject-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Part: Pharmacokinetic parameters of CPI-0610 and ruxolitinib: AUC and Cmax</measure>
    <time_frame>Assessed during cycle 1 (first 21 days on study)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">271</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Leukemia, Myelocytic, Acute</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi.(CPI-0610 alone)
Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Prior JAKi Combination Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)
Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: JAKi Naïve Combination Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Open to patients with MF who are anemic (i.e., Hemoglobin (Hgb) &lt;10g/dL) and who have not previously received a JAKi. (CPI-0610 + Ruxolitinib)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-0610</intervention_name>
    <arm_group_label>Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm</arm_group_label>
    <arm_group_label>Arm 2: Prior JAKi Combination Arm</arm_group_label>
    <arm_group_label>Arm 3: JAKi Naïve Combination Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <arm_group_label>Arm 2: Prior JAKi Combination Arm</arm_group_label>
    <arm_group_label>Arm 3: JAKi Naïve Combination Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Adult (aged ≥ 18 years)

          -  Phase 2 part: Patients with confirmed diagnosis of MF who meet all of the following
             criteria:

               -  Dynamic International Prognostic Scoring System (DIPSS) risk category of
                  intermediate-1 or higher.

               -  ANC ≥ 1 x 10^9/L without the assistance of granulocyte growth factors

               -  Peripheral blood blast count &lt;10%

          -  ECOG performance status ≤ 2.

          -  Adequate hematological, renal, hepatic, and coagulation laboratory assessments

          -  Patients must give written informed consent to participate in this study before the
             performance of any study-related procedure.

        For Arm 1 and 2 the following criteria should be considered:

          -  Palpable spleen ≥ 5 cm that is below the costal margin on physical examination OR RBC
             transfusion dependent (defined as an average of ≥2 units of RBC transfusions per month
             over the 12 weeks prior to enrollment)

          -  At least 2 symptoms measurable (score ≥ 1) using the Myelofibrosis Symptom Assessment
             Form Version 4.0 (MFSAF v4.0)

          -  Platelet count ≥ 75 x 10^9/L without the assistance of thrombopoietic factors or
             transfusions for at least 14 days

          -  Monotherapy Arm (Arm 1): Previously treated with a JAK inhibitor and be intolerant,
             resistant, refractory or lost response to the JAK inhibitor

          -  Combination Arm (Arm 2): Must have received single agent ruxolitinib and be on a
             stable dose for a minimum 8 weeks

        For Arm 3 (JAK inhibitors naïve) the following criteria should be considered:

          -  Platelet count ≥ 100 x 10^9/L without the assistance of thrombopoietic factors or
             transfusions

          -  Palpable spleen ≥ 5 cm that is below the costal margin on physical examination

          -  At least 2 symptoms measurable (score ≥ 3) or a total score of ≥ 10 using the MFSAF
             v4.0

          -  No prior treatment with JAKi allowed

        Exclusion Criteria

          -  Current known active or chronic infection with human immunodeficiency virus (HIV),
             Hepatitis B or Hepatitis C.

          -  Impaired cardiac function or clinically significant cardiac diseases

          -  Patients with Child-Pugh Class B or C

          -  Impairment of gastrointestinal (GI) function or GI disease that could significantly
             alter the absorption of CPI-0610 and/or ruxolitinib, including any unresolved nausea,
             vomiting, or diarrhea that is CTCAE grade &gt;1

          -  Prior treatment with a BET inhibitor.

          -  Pregnant or lactating women

          -  Any other concurrent severe and/or uncontrolled concomitant medical condition that
             could compromise participation in the study

          -  Patients unwilling or unable to comply with this study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debbie Johnson</last_name>
    <role>Study Director</role>
    <affiliation>Constellation Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie Johnson</last_name>
    <phone>617-714-0555</phone>
    <email>debbie.johnson@constellationpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farzam Hariri</last_name>
      <email>FHariri@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Center</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wael Harb, MD</last_name>
      <phone>765-446-5111</phone>
      <email>info@horizonbioadvance.com</email>
    </contact>
    <investigator>
      <last_name>Wael Harb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Connolly</last_name>
      <phone>617-726-5131</phone>
      <email>cconnolly1@partners.org</email>
    </contact>
    <investigator>
      <last_name>Gabriela Hobbs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D'Andra Featherstone</last_name>
      <phone>734-936-2712</phone>
      <email>dandrah@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Moshe Talpaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicne Neuromuscular Division Department of neurology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Gaudin</last_name>
      <phone>314-747-7960</phone>
      <email>nrgaudin@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karyn Gordon</last_name>
      <phone>314-362-0156</phone>
      <email>kdgordon@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmounth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maddie Shukla</last_name>
      <email>shuklam@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Rajit Rampal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maddie Shukla</last_name>
      <email>shuklam@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Rajit Rampal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maddie Shukla</last_name>
      <email>shuklam@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Rajit Rampal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Fabris</last_name>
      <phone>212-241-8999</phone>
      <email>frank.fabris@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Marina Kremyanskya, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Centre</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mackenzie Snead</last_name>
      <email>mbs2173@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Heaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maddie Shukla</last_name>
      <email>shuklam@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Raajit Rampal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College-New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Hoberman</last_name>
    </contact>
    <investigator>
      <last_name>Joseph Scandura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith, RN</last_name>
      <email>CSmith@GabrailCancerCenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romany Gergis</last_name>
      <phone>713-792-9116</phone>
      <email>RGergis@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Prithviraj Bose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Rackel</last_name>
      <phone>780-407-1811</phone>
      <email>lori.rackel@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Elena Liew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Despotovic</last_name>
      <phone>604-875-5296</phone>
      <email>rachel.despotovic@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Lynda Foltz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Shore</last_name>
      <email>elisa.shore@jcc.hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Brian Leber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Foley</last_name>
      <phone>(416) 946-4501</phone>
      <email>Kelly.Foley@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Vikas Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabina Naqvi</last_name>
      <phone>416-581-8619</phone>
      <email>sabina.naqvi@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Vikas Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adele Cascini</last_name>
      <phone>514-340-2222</phone>
      <email>acascini@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Shireen Sirhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Oncology</keyword>
  <keyword>BET Inhibitor</keyword>
  <keyword>Ruxolitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

